Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition

Clovis Oncology Inc CLVS announced two abstracts featuring non-clinical data from studies evaluating FAP-2286 and Rubraca and a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE study.

  • In a new non-clinical data analysis, FAP-2286 demonstrated a potent human fibroblast activation protein (FAP) affinity by biochemical and cell-based assays. 
  • Additionally, lutetium-177 (177Lu)-FAP-2286 showed longer tumor retention, resulting in more significant tumor inhibition than lutetium-177 (177Lu)-FAPI-46, a FAP-targeted radiotracer developed for therapeutic applications at the University of Heidelberg, Germany.
  • Approximately 50 patients will be enrolled in the Phase 1 portion of LuMIERE trial, which is currently enrolling patients with advanced solid tumors. 
  • Related: Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status.
  • The Phase 1 portion is evaluating the safety of 177Lu-FAP-2286 and will identify the recommended Phase 2 dose and schedule. 
  • Phase 2 expansion cohorts in multiple tumor types are planned for later in 2022.
  • Separately, non-clinical data evaluating Rubraca efficacy in a panel of tumors with deleterious alterations in a core group of non-BRCA HRR genes showed responses similar to the efficacy observed in BRCA1/2-altered models.
  • Price Action: CLVS shares are down 1.85% at $2.65 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!